Transcranial Direct-current Stimulation (tDCS) Efficacy in Refractory Cancer Pain.

  • STATUS
    Recruiting
  • End date
    Jun 15, 2023
  • participants needed
    70
  • sponsor
    Elsan
Updated on 15 October 2021
analgesics
opioid
cancer
analgesic
chronic pain
cancer pain
palliative care
neuropathic pain

Summary

Pain is a common symptom in palliative care cancer patients and is often insufficiently relieved. The 2010 INCA report showed that France is not an exception to this worldwide observation (synopsis of the 2010 national survey). This report shows that pain is the symptom that these patients fear the most and that it dramatically impacts their quality of life. These patients may experience nociceptive pain related to stimulation of sensory nerve endings by the tumour. When tumour resection is impossible, a symptomatic analgesic treatment is generally proposed, mainly consisting of administration of opioid analgesics. At high doses, this treatment induces adverse effects, especially drowsiness and psychomotor retardation that impair the patient's quality of life.

They may also experience neuropathic pain, secondary to anatomical lesions or functional impairment of nerve structures (peripheral nerves or cerebral or spinal tracts) related to repeated surgical procedures and/or radiotherapy. This type of pain may respond to antiepileptic or antidepressant drugs. At high doses, these treatments also induce adverse effects fairly similar to those observed during treatment of nociceptive pain. As these two types of treatment often need to be coprescribed, these patients frequently present an almost permanent state of drowsiness at the end of life, preventing all normal activities of daily living.

In recent years, noninvasive brain stimulation (NIBS) techniques (transcranial magnetic stimulation (rTMS) or transcranial direct-current stimulation (tDCS)) have been successfully used to treat chronic pain. It was shown that these NIBS techniques can improve pain in cancer patients in the palliative care setting.

Description

tDCS appears to be more suitable than rTMS for the treatment of palliative care patients, who are often difficult to mobilize, as tDCS can be delivered at the patient's bedside and possibly even at home, which is not the case with rTMS. tDCS also appears to be rapidly effective (after 5 sessions) in the context of cancer pain, and this effect lasts longer than that of rTMS.

The proposed treatment of refractory cancer pain by tDCS in palliative care patients is a new treatment modality that is well adapted to hospitalised patients. Each patient will receive 20 minutes of transcranial direct-current stimulation daily for 5 consecutive days.

One arm will receive active stimulation and the control arm will receive sham stimulation. Patients and investigators will be blinded to the type of tDCS.

By improving the patient's activities of daily living, this treatment will enable the patient to return home under good conditions for both the patient and the caregivers. This treatment can also be continued at home. This strategy is consistent with current guidelines in this field, in which the priorities are improvement of quality of life, return home and decreased workload for caregivers.

Details
Condition Cancer Pain, Post-Surgical Pain, intractable pain, refractory pain, Pain, Pain (Pediatric)
Treatment Sham transcranial direct current stimulation, active transcranial direct current stimulation
Clinical Study IdentifierNCT04683172
SponsorElsan
Last Modified on15 October 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patient with a confirmed cancer at a palliative stage
Pain whose mean intensity is greater than or equal to 4/10 in the 48 hours preceding inclusion
Pain present on a daily or almost daily basis (at least 4 days out of 7)
Pain that has been present for at least 48 hours before inclusion
Patients aged 18 or over
Patients who can be followed for the duration of the study (i.e. 3 weeks)
Patients affiliated to a health insurance plan or entitled
Life expectancy estimated at more than 3 weeks
Agreeing to participate in the study and having signed an informed consent

Exclusion Criteria

Inability to self-assess pain and complete self-questionnaires
History of head trauma or neurosurgical injury
Symptomatic intracranial hypertension (HTIC)
Uncontrolled epilepsy
Impossibility to correctly positioning the medical device
Abuse of drugs or psychoactive substances, at the discretion of the investigator
Current major depression or psychosis
Pregnant or breastfeeding woman
Patient already included in a research protocol on pain
Patient under legal protection
Absence of affiliation to a social security scheme
Specific contraindication to tDCS (intracerebral metal implant)
Patients deprived of liberty
Patients undergoing psychiatric care
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note